No Data
No Data
Shanghai Fosun Pharma's New Cancer Drug Application Accepted
FOSUN PHARMA (600196.SH): The registration application for the injectable Raltitrexed Pharmaceutical has been accepted.
FOSUN PHARMA (600196.SH) announced that its controlling subsidiary, Gismay (Wuhan) Pharmaceutical Co., Ltd. ...
On December 30, FOSUN PHARMA (02196.HK) spent 4.94 million Hong Kong dollars to repurchase 0.35 million shares.
Gelonghui reported on December 30 that FOSUN PHARMA (02196.HK) announced that on December 30, it spent 4.94 million Hong Kong dollars to repurchase 0.35 million shares.
How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.
On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.
Guangxi Wuzhou Zhongheng Group (600252.SH): A subsidiary plans to participate in the establishment of FOSUN PHARMA (Nanning) Co., Ltd.
Gelonghui reported on December 27 that Guangxi Wuzhou Zhongheng Group (600252.SH) announced that in order to meet the needs of the company's Business development, further expand the layout of the overseas market Business and enhance comprehensive competitiveness, Guangxi Wuzhou Zhongheng Group's wholly-owned subsidiary Zhongheng Yixin plans to establish a joint venture with the wholly-owned subsidiary of FOSUN PHARMA, Shanghai FOSUN PHARMA Industrial Development Co., Ltd. (referred to as "FOSUN Industrial Company"), and Nanning Industry Investment Unified Investment Group Co., Ltd. (referred to as "Unified Investment Group"). The registered capital of the joint venture is 100 million yuan, of which FOSUN Industrial Company contributes 5,100.
On December 27, FOSUN PHARMA (02196.HK) spent 2.8723 million Hong Kong dollars to repurchase 0.2045 million shares.
On December 27, Gelonghui reported that FOSUN PHARMA (02196.HK) announced the repurchase of 0.2045 million shares for HKD 2.8723 million on December 27, 2024, with a repurchase price of HKD 13.94-14.1 per share.
No Data